Monotherapy for estrogen-receptor +ve, human epidermal growth factor receptor 2 (HER2) -ve locally advanced or metastatic breast cancer in postmenopausal women not previously treated w/ endocrine therapy or w/ disease relapse on or after adjuvant endocrine therapy, or disease progression on endocrine therapy. In combination w/ ribociclib for hormone receptor (HR) +ve, HER2 -ve advanced or metastatic breast cancer in postmenopausal women as initial endocrine based therapy or following disease progression on endocrine therapy. In combination w/ abemaciclib for HR +ve, HER2 -ve advanced or metastatic breast cancer w/ disease progression following endocrine therapy. In combination w/ palbociclib for HR +ve, HER2 -ve locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
Sign Out
